BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare

1,432 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBIO Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$86.20

▲(16.39% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $86.20 with a high forecast of $100.00 and a low forecast of $69.00. The average price target represents a 16.39% change from the last price of $74.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","44":"$44","63":"$63","82":"$82","101":"$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,44,63,82,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.78,73.95076923076923,76.12153846153846,78.29230769230769,80.46307692307693,82.63384615384615,84.80461538461539,86.97538461538461,89.14615384615385,91.31692307692308,93.48769230769231,95.65846153846154,97.82923076923078,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.78,72.88923076923076,73.99846153846154,75.1076923076923,76.21692307692308,77.32615384615384,78.43538461538462,79.54461538461538,80.65384615384616,81.76307692307692,82.8723076923077,83.98153846153846,85.09076923076924,{"y":86.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.78,71.56615384615385,71.35230769230769,71.13846153846154,70.92461538461538,70.71076923076923,70.49692307692308,70.28307692307692,70.06923076923077,69.85538461538462,69.64153846153846,69.42769230769231,69.21384615384615,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$86.20

Lowest Price Target$69.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Pickering

Bernstein

$94

Buy

26.92%

Upside

Initiated

12/11/25

BridgeBio Pharma: Buy Rating Backed by Promising Drug Pipeline and Strategic Market PositioningWe initiate on BBIO with an Outperform rating and $94 PT. We believe expectations for ATTR-CM drug Attruby are reasonable near/mid-term and arguably too high long term, while we see upside to consensus numbers for infigratinib and encaleret. We are in line for BBP-418. Key proprietary analyses in this initiation: ATTR-CM doc survey, infigratinib doc feedback, infigratinib Ph3 trial analysis.

Biren Amin

Piper Sandler

$98

Buy

32.33%

Upside

Reiterated

12/04/25

Andrew Tsai

Jefferies

$85

Buy

14.77%

Upside

Reiterated

11/24/25

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

Tiago Fauth

Wells Fargo

$76→$84

Buy

13.42%

Upside

Reiterated

11/11/25

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)We Like the 2026 Setup after Refreshing Our View on Attruby Ramp + Pipeline Upside; Raising Price Target to $84

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Wave Life Sciences (NASDAQ: WVE) and BridgeBio Pharma (NASDAQ: BBIO)

Anupam Rama

J.P. Morgan

$76→$77

Buy

3.97%

Upside

Reiterated

11/07/25

BridgeBio price target raised to $77 from $76 at JPMorganBridgeBio price target raised to $77 from $76 at JPMorgan

Ram Selvaraju

H.C. Wainwright

$90

Buy

21.52%

Upside

Reiterated

11/03/25

H.C. Wainwright Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)We reiterate our Buy rating and 12‐month price target of $90.

Salim Syed

Mizuho Securities

$64→$91

Buy

22.87%

Upside

Reiterated

11/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Choi

Goldman Sachs

$55→$100

Buy

35.03%

Upside

Reiterated

10/31/25

Goldman Sachs Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Cory Kasimov

Evercore ISI

$75→$90

Buy

21.52%

Upside

Reiterated

10/30/25

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Trevor Allred

Oppenheimer

$73→$81

Buy

9.37%

Upside

Reiterated

10/30/25

BridgeBio price target raised to $81 from $73 at OppenheimerBridgeBio price target raised to $81 from $73 at Oppenheimer

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$73→$81

Buy

9.37%

Upside

Reiterated

10/30/25

BridgeBio Pharma (BBIO) Gets a Buy from Roth MKMWe remain Outperform-rated; PT to $81 from $73.

Jason Zemansky

Bank of America Securities

$58→$76

Buy

2.62%

Upside

Reiterated

10/29/25

Analysts' Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)

Tyler Van Buren

TD Cowen

$60→$95

Buy

28.27%

Upside

Reiterated

10/29/25

TD Cowen Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)We remain Buy.

Martin Auster

Raymond James

$56→$69

Buy

-6.83%

Downside

Reiterated

10/27/25

BridgeBio Pharma's Promising Phase 3 Results and Accelerated Approval Path Justify Buy RatingWe maintain our Outperform rating and raise our PT to $69.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Pickering

Bernstein

$94

Buy

26.92%

Upside

Initiated

12/11/25

Biren Amin

Piper Sandler

$98

Buy

32.33%

Upside

Reiterated

12/04/25

Andrew Tsai

Jefferies

$85

Buy

14.77%

Upside

Reiterated

11/24/25

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

Tiago Fauth

Wells Fargo

$76→$84

Buy

13.42%

Upside

Reiterated

11/11/25

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)We Like the 2026 Setup after Refreshing Our View on Attruby Ramp + Pipeline Upside; Raising Price Target to $84

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Wave Life Sciences (NASDAQ: WVE) and BridgeBio Pharma (NASDAQ: BBIO)

Anupam Rama

J.P. Morgan

$76→$77

Buy

3.97%

Upside

Reiterated

11/07/25

BridgeBio price target raised to $77 from $76 at JPMorganBridgeBio price target raised to $77 from $76 at JPMorgan

Ram Selvaraju

H.C. Wainwright

$90

Buy

21.52%

Upside

Reiterated

11/03/25

H.C. Wainwright Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)We reiterate our Buy rating and 12‐month price target of $90.

Salim Syed

Mizuho Securities

$64→$91

Buy

22.87%

Upside

Reiterated

11/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Choi

Goldman Sachs

$55→$100

Buy

35.03%

Upside

Reiterated

10/31/25

Goldman Sachs Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Cory Kasimov

Evercore ISI

$75→$90

Buy

21.52%

Upside

Reiterated

10/30/25

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Trevor Allred

Oppenheimer

$73→$81

Buy

9.37%

Upside

Reiterated

10/30/25

BridgeBio price target raised to $81 from $73 at OppenheimerBridgeBio price target raised to $81 from $73 at Oppenheimer

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$73→$81

Buy

9.37%

Upside

Reiterated

10/30/25

BridgeBio Pharma (BBIO) Gets a Buy from Roth MKMWe remain Outperform-rated; PT to $81 from $73.

Jason Zemansky

Bank of America Securities

$58→$76

Buy

2.62%

Upside

Reiterated

10/29/25

Analysts' Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)

Tyler Van Buren

TD Cowen

$60→$95

Buy

28.27%

Upside

Reiterated

10/29/25

TD Cowen Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)We remain Buy.

Martin Auster

Raymond James

$56→$69

Buy

-6.83%

Downside

Reiterated

10/27/25

BridgeBio Pharma's Promising Phase 3 Results and Accelerated Approval Path Justify Buy RatingWe maintain our Outperform rating and raise our PT to $69.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+6.15%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +6.15% per trade.

3 Months

xxx

Success Rate

14/16 ratings generated profit

Average Return

+29.51%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +29.51% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

15/15 ratings generated profit

Average Return

+84.87%

reiterated a buy rating 2 months ago

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +84.87% per trade.

2 Years

xxx

Success Rate

24/24 ratings generated profit

Average Return

+137.97%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +137.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBIO has received 25 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 86.20.

Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.73 with a range of -$0.91 to -$0.51. The previous quarter’s EPS was -$0.95. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $145.90M with a range of $126.00M to $217.49M. The previous quarter’s sales results were $120.70M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 86.20.

What is BBIO’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 16.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBIO a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s price target?

The average price target for BridgeBio Pharma Inc is 86.20. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $69.00. The average price target represents 16.39% Increase from the current price of $74.06.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of BBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BBIO Analyst Ratings

BBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

BBIO Analyst Recommendation Trends

BBIO Financial Forecast

BBIO Earnings Forecast

BBIO Sales Forecast

BBIO Stock Forecast FAQ

Detailed List of Analyst Forecasts